JP2002514228A - 受容体チロシンキナーゼ阻害剤、特にｒａｆキナーゼ阻害剤としてのベンジリン−１，３−ジヒドロ−インドール−２−オン誘導体 - Google Patents

受容体チロシンキナーゼ阻害剤、特にｒａｆキナーゼ阻害剤としてのベンジリン−１，３−ジヒドロ−インドール−２−オン誘導体

Info

Publication number
JP2002514228A
JP2002514228A JP51383999A JP51383999A JP2002514228A JP 2002514228 A JP2002514228 A JP 2002514228A JP 51383999 A JP51383999 A JP 51383999A JP 51383999 A JP51383999 A JP 51383999A JP 2002514228 A JP2002514228 A JP 2002514228A
Authority
JP
Japan
Prior art keywords
aliphatic
het
optionally
aryl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP51383999A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002514228A5 (https=
Inventor
ジュニア ロバート、ウォルトン、マックナット
デイビッド、ケンダル、ユング
フィリップ、アンソニー、ハリス
ロバート、ニール、ハンター、ザ、サード
ジェイムズ、マービン、ビール
スコット、ディッカーソン
カレン、エリザベス、ラッキー
マイケル、ロバート、ピール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2002514228A publication Critical patent/JP2002514228A/ja
Publication of JP2002514228A5 publication Critical patent/JP2002514228A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP51383999A 1997-08-06 1998-08-04 受容体チロシンキナーゼ阻害剤、特にｒａｆキナーゼ阻害剤としてのベンジリン−１，３−ジヒドロ−インドール−２−オン誘導体 Ceased JP2002514228A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9716557.5 1997-08-06
GBGB9716557.5A GB9716557D0 (en) 1997-08-06 1997-08-06 Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
PCT/EP1998/004844 WO1999010325A1 (en) 1997-08-06 1998-08-04 Benzylidene-1,3-dihydro-indol-2-one derivatives as receptor tyrosine kinase inhibitors, particularly of raf kinases

Publications (2)

Publication Number Publication Date
JP2002514228A true JP2002514228A (ja) 2002-05-14
JP2002514228A5 JP2002514228A5 (https=) 2006-01-05

Family

ID=10817030

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51383999A Ceased JP2002514228A (ja) 1997-08-06 1998-08-04 受容体チロシンキナーゼ阻害剤、特にｒａｆキナーゼ阻害剤としてのベンジリン−１，３−ジヒドロ−インドール−２−オン誘導体

Country Status (13)

Country Link
US (1) US6268391B1 (https=)
EP (1) EP1003721B1 (https=)
JP (1) JP2002514228A (https=)
AR (1) AR016789A1 (https=)
AT (1) ATE344241T1 (https=)
AU (1) AU9158498A (https=)
DE (1) DE69836332T2 (https=)
ES (1) ES2272008T3 (https=)
GB (1) GB9716557D0 (https=)
MA (1) MA26529A1 (https=)
PE (1) PE112699A1 (https=)
WO (1) WO1999010325A1 (https=)
ZA (1) ZA987037B (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080392A1 (ja) * 2004-02-19 2005-09-01 Takeda Pharmaceutical Company Limited ピラゾロキノロン誘導体およびその用途
JP2005532284A (ja) * 2002-04-03 2005-10-27 アラーガン、インコーポレイテッド キナーゼ阻害物質としての（３ｚ）−３−（３−ヒドロ−イソベンゾフラン−１−イリデン）−１，３−ジヒドロ−２ｈ−インドール−２−オン類
JP2007528884A (ja) * 2004-03-12 2007-10-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規なシクロアルキル含有５−アシルインドリノン、その製法及びその医薬品としての使用
JP2010538091A (ja) * 2007-09-06 2010-12-09 ボストン バイオメディカル， インコーポレイテッド キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用
JP2016513656A (ja) * 2013-03-13 2016-05-16 ボストン バイオメディカル， インコーポレイテッド がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての３−（アリールまたはヘテロアリール）メチレンインドリン−２−オン誘導体

Families Citing this family (237)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
CA2222545A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Quinazolines and pharmaceutical compositions
US6316635B1 (en) 1995-06-07 2001-11-13 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US6906093B2 (en) 1995-06-07 2005-06-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US6147106A (en) 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US6696448B2 (en) 1996-06-05 2004-02-24 Sugen, Inc. 3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
JP4713698B2 (ja) 1997-03-05 2011-06-29 スージェン， インク． 疎水性薬剤の処方
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6486185B1 (en) 1997-05-07 2002-11-26 Sugen, Inc. 3-heteroarylidene-2-indolinone protein kinase inhibitors
US6316429B1 (en) 1997-05-07 2001-11-13 Sugen, Inc. Bicyclic protein kinase inhibitors
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
US6987113B2 (en) 1997-06-11 2006-01-17 Sugen, Inc. Tyrosine kinase inhibitors
US6051593A (en) * 1997-06-20 2000-04-18 Sugen, Inc. 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
US6114371A (en) * 1997-06-20 2000-09-05 Sugen, Inc. 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
US6313158B1 (en) 1997-06-20 2001-11-06 Sugen, Inc. Bioavailability of 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors
US6130238A (en) * 1997-06-20 2000-10-10 Sugen, Inc. 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
US6235769B1 (en) 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
US6133305A (en) 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6531502B1 (en) 1998-01-21 2003-03-11 Sugen, Inc. 3-Methylidenyl-2-indolinone modulators of protein kinase
US6514981B1 (en) 1998-04-02 2003-02-04 Sugen, Inc. Methods of modulating tyrosine protein kinase function with indolinone compounds
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
EA005032B1 (ru) 1998-05-29 2004-10-28 Сьюджен, Инк. Пирролзамещенные 2-индолиноны (варианты), фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
US6153634A (en) 1998-12-17 2000-11-28 Hoffmann-La Roche Inc. 4,5-azolo-oxindoles
CN1158283C (zh) * 1998-12-17 2004-07-21 霍夫曼-拉罗奇有限公司 作为蛋白激酶抑制剂的4-和5-吡嗪基羟吲哚
EP1149093A1 (en) 1998-12-17 2001-10-31 F. Hoffmann-La Roche Ag 4-aryloxindoles as inhibitors of jnk protein kinases
BR9916327A (pt) * 1998-12-17 2001-09-18 Hoffmann La Roche Oxindóis de 4-alquenila (e alquinila) como inibidores de cinases dependentes de ciclina, em particular, cdk2
GB9904932D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
US7064114B2 (en) 1999-03-19 2006-06-20 Parker Hughes Institute Gel-microemulsion formulations
US6689806B1 (en) 1999-03-24 2004-02-10 Sugen, Inc. Indolinone compounds as kinase inhibitors
AU3770000A (en) * 1999-03-24 2000-10-09 Sugen, Inc. Indolinone compounds as kinase inhibitors
JP2000281588A (ja) * 1999-03-30 2000-10-10 Sankyo Co Ltd ガンの予防又は治療薬及びそのスクリーニング方法
EP1173254A2 (en) * 1999-04-27 2002-01-23 Smithkline Beecham Plc Novel treatment of neurotraumatic conditions with a raf inhibitor
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
US6313310B1 (en) 1999-12-15 2001-11-06 Hoffmann-La Roche Inc. 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
EP1255536B1 (en) 1999-12-22 2006-06-28 Sugen, Inc. Indolinone derivatives for modulation of c-kit tyrosine protein kinase
US6339100B1 (en) * 1999-12-29 2002-01-15 The Trustees Of Columbia University In The City Of New York Methods for inhibiting mastocytosis
WO2001056557A2 (en) * 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of erk
SI1255752T1 (sl) 2000-02-15 2007-12-31 Pharmacia & Upjohn Co Llc S pirolom substituirani zaviralci 2-indolinon protein kinaza
US6620818B1 (en) 2000-03-01 2003-09-16 Smithkline Beecham Corporation Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
JP2003535847A (ja) 2000-06-02 2003-12-02 スージェン・インコーポレーテッド 蛋白質キナーゼ／ホスファターゼ阻害剤としてのインドリノン誘導体
GB0016454D0 (en) 2000-07-04 2000-08-23 Hoffmann La Roche Thienopyrrolidinones
CA2417500C (en) * 2000-07-28 2008-11-18 Georgetown University Medical Center Erbb-2 selective small molecule kinase inhibitors
ES2230337T3 (es) 2000-09-01 2005-05-01 Glaxo Group Limited Derivados de oxindol.
US6638965B2 (en) 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
DE10054019A1 (de) * 2000-11-01 2002-05-23 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
EP1512413A3 (en) 2001-01-16 2009-09-23 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
WO2002070478A1 (en) 2001-03-06 2002-09-12 Astrazeneca Ab Indolone derivatives having vascular-damaging activity
AU2002303892A1 (en) 2001-05-30 2002-12-09 Jingrong Cui 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
DE10134196B4 (de) 2001-07-13 2005-08-18 Forschungszentrum Karlsruhe Gmbh Technik Und Umwelt Pharmazeutische Zusammensetzung zur Hemmung der unkontrollierten Vermehrung und/oder Induzierung der Apoptose von Zellen
ATE343575T1 (de) * 2001-09-27 2006-11-15 Smithkline Beecham Corp Azaoxoindol derivate als trk protein kinase hemmstoffe zur behandlung von krebs und chronischem schmerz
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US20030119839A1 (en) * 2001-12-13 2003-06-26 Nan-Horng Lin Protein kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
GB0206861D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Medicaments
US6541504B1 (en) 2002-04-03 2003-04-01 Allergan Sales, Llc (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
AU2003221684A1 (en) * 2002-04-08 2003-10-27 Smithkline Beecham Corporation Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
ITMI20021620A1 (it) * 2002-07-23 2004-01-23 Novuspharma Spa Composto ad ativita' antitumorale
US7585866B2 (en) * 2002-07-31 2009-09-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
CA2496164C (en) * 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
PT1537116E (pt) 2002-09-04 2010-09-03 Schering Corp Pirazolopirimidinas adequadas para o tratamento de doenças cancerosas
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
AU2003273675A1 (en) * 2002-10-09 2004-05-04 Wayne R. Danter Protein tyrosine kinase inhibitors
AU2003290699B2 (en) * 2002-11-13 2009-08-27 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
WO2004050681A2 (en) * 2002-11-15 2004-06-17 Exelixis, Inc. Kinase modulators
US20050019366A1 (en) * 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
WO2004064733A2 (en) * 2003-01-15 2004-08-05 Board Of Regents, University Of Texas System The use of c-raf inhibitors for the treatment of neurodegenerative diseases
CA2526594C (en) * 2003-05-27 2011-11-08 Robert Per Haegerkvist Use of tyrosine kinase inhibitors to treat diabetes
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
PT1682126E (pt) * 2003-10-16 2009-10-02 Novartis Vaccines & Diagnostic Benzazois substituídos e sua utilização como inibidores da quinase raf
CN102225926A (zh) * 2003-11-07 2011-10-26 诺华疫苗和诊断公司 具有改进药物特性的喹啉酮类化合物的药学上可接受的盐
WO2005068424A1 (en) * 2004-01-20 2005-07-28 Cell Therapeutics Europe S.R.L. Indolinone derivatives as receptor tyrosine kinase ihibitors
US7875624B2 (en) * 2004-02-20 2011-01-25 Novartis Vaccines And Diagnostics, Inc. Modulating and measuring cellular adhesion
SG176463A1 (en) 2005-02-22 2011-12-29 Univ Michigan Small molecule inhibitors of mdm2 and uses thereof
CA2608171C (en) * 2005-05-13 2014-02-04 Novartis Ag Use of quinolinone compounds for treating drug resistant cancers
MX2007014782A (es) 2005-05-23 2008-02-19 Novartis Ag Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona.
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
RU2433826C2 (ru) * 2005-11-29 2011-11-20 Новартис Аг Композиции хинолинонов
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
MX2008010635A (es) 2006-02-16 2008-10-28 Schering Corp Derivados de pirrolidina como inhibidores de cinasa regulada por señales extracelulares.
EP2046292B1 (en) * 2006-07-21 2010-03-03 Novartis AG Formulations for benzimidazolyl pyridyl ethers
KR20090071603A (ko) * 2006-09-19 2009-07-01 노파르티스 아게 Ｒａｆ 억제제에 대한 표적 조절, 효능, 진단 및/또는 예후의 바이오마커
JP5571387B2 (ja) 2007-01-11 2014-08-13 クリティカル・アウトカム・テクノロジーズ・インコーポレイテッド 癌の治療のための化合物および方法
KR100799821B1 (ko) * 2007-02-05 2008-01-31 동화약품공업주식회사 신규한 이마티닙 캠실레이트 및 그의 제조방법
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
UY30915A1 (es) 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
US20110129550A1 (en) 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
US20100143440A1 (en) * 2007-04-30 2010-06-10 The Uab Research Foundation Ul97 inhibitors for treatment of proliferative disorders
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
EP2181987B9 (en) 2007-08-23 2014-09-03 Takeda Pharmaceutical Company Limited 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer
US8344135B2 (en) 2007-08-29 2013-01-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US8530508B2 (en) * 2007-10-09 2013-09-10 Glaxosmithkline Llc Thrombopoietin receptor agonist (TpoRA) kills acute human myeloid leukemia cells
EP2235004A4 (en) 2007-12-21 2011-05-04 Univ Health Network INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT
CA2710039C (en) * 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
WO2009105500A1 (en) 2008-02-21 2009-08-27 Schering Corporation Compounds that are erk inhibitors
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
JP5743897B2 (ja) 2008-11-20 2015-07-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 化合物
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
ES2467108T3 (es) 2008-12-09 2014-06-11 Gilead Sciences, Inc. Moduladores de receptores tipo toll
US20110288142A1 (en) 2009-01-30 2011-11-24 Chen Pingyun Y CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
JP5629752B2 (ja) 2009-04-06 2014-11-26 ユニバーシティ・ヘルス・ネットワークＵｎｉｖｅｒｓｉｔｙ Ｈｅａｌｔｈ Ｎｅｔｗｏｒｋ キナーゼインヒビターおよびこれを用いた癌の治療方法
US8410095B2 (en) 2009-05-20 2013-04-02 Glaxosmithkline Llc Thiazolopyrimidinone derivatives as PI3 kinase inhibitors
PE20121148A1 (es) 2009-08-17 2012-09-07 Intellikine Llc Compuestos heterociclicos y usos de los mismos
HUE029098T2 (en) 2009-08-21 2017-02-28 Novartis Ag To treat lapatinib cancer
CN102596969A (zh) 2009-08-26 2012-07-18 赛林药物股份有限公司 用作蛋白激酶调节剂的稠合喹啉类化合物
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
NO2477987T3 (https=) 2009-09-14 2018-06-09
US8703781B2 (en) 2009-10-16 2014-04-22 Glaxosmithkline Llc Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
US8962652B2 (en) 2009-10-22 2015-02-24 Gilead Sciences, Inc. Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
WO2011057204A2 (en) * 2009-11-06 2011-05-12 The Johns Hopkins University Lrrk2-mediated neuronal toxicity
US9181238B2 (en) 2010-02-05 2015-11-10 Novartis Ag N-(pyridin-2-yl)sulfonamides and compositions thereof as protein kinase inhibitors
CA2794153C (en) 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
JP5442906B2 (ja) 2010-04-06 2014-03-19 ユニバーシティ・ヘルス・ネットワーク キナーゼインヒビターおよびこれを用いた癌の治療方法
US20130096149A1 (en) 2010-06-25 2013-04-18 Novartis Ag Heteroaryl compounds and compositions as protein kinase inhibitors
US20130172378A1 (en) 2010-09-14 2013-07-04 Glaxosmithkline Llc Combination of BRAF and VEGF Inhibitors
JP5719028B2 (ja) 2010-10-06 2015-05-13 グラクソスミスクライン エルエルシー Ｐｉ３キナーゼ阻害剤としてのベンズイミダゾール誘導体
GB201112607D0 (en) 2011-07-22 2011-09-07 Glaxo Group Ltd Novel compounds
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
JP6100700B2 (ja) 2011-01-11 2017-03-22 ノバルティス アーゲー 組合せ
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
CN108542906A (zh) 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
ES2695099T3 (es) 2011-11-23 2019-01-02 Array Biopharma Inc Formulaciones farmacéuticas
WO2013113796A1 (en) 2012-01-31 2013-08-08 Smithkline Beecham (Cork) Limited Method of treating cancer
WO2013143597A1 (en) 2012-03-29 2013-10-03 Glaxo Group Limited Demethylase enzymes inhibitors
RU2015118647A (ru) 2012-11-20 2017-01-10 Дженентек, Инк. Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr
AU2013352369B2 (en) 2012-11-30 2016-07-28 Novartis Ag. Novel pharmaceutical composition
EP2943199A1 (en) 2013-01-09 2015-11-18 Glaxosmithkline Intellectual Property (No. 2) Limited Combination
ES2651331T3 (es) 2013-01-10 2018-01-25 Glaxosmithkline Intellectual Property (No. 2) Limited Inhibidores de la sintasa de ácidos grasos
GB201311910D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel Compounds
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
SG11201509742QA (en) 2013-06-03 2015-12-30 Novartis Ag Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
WO2014210354A1 (en) 2013-06-28 2014-12-31 Genentech, Inc. Azaindazole compounds as inhibitors of t790m containing egfr mutants
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
ES3063787T3 (en) 2013-10-01 2026-04-20 Novartis Ag Composition comprising a 17 a-hydroxylase/c17,20 lyase (cyp17a1) inhibitor and an akt inhibitor
JP6355724B2 (ja) 2013-10-01 2018-07-11 ノバルティス アーゲー がんを治療するためのアフレセルチブと組み合わせたエンザルタミド
WO2015056180A1 (en) 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Indoline derivatives as inhibitors of perk
SG11201602882VA (en) 2013-10-18 2016-05-30 Univ Health Network Treatment for pancreatic cancer
CN106029074A (zh) 2013-12-12 2016-10-12 诺华股份有限公司 用于治疗癌症的曲美替尼、帕尼单抗和达拉菲尼组合
WO2015128837A1 (en) 2014-02-26 2015-09-03 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer patients responding to ezh2 inhibitor gsk126
EP3116546A1 (en) 2014-03-12 2017-01-18 Novartis AG Combination comprising a btk inhibitor and an akt inhibitor
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
PT3166607T (pt) 2014-07-11 2022-12-07 Gilead Sciences Inc Moduladores de receptores de tipo toll para o tratamento do vih
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CA2960436C (en) 2014-09-16 2021-01-05 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2016055935A1 (en) 2014-10-06 2016-04-14 Glaxosmithkline Intellectual Property (No.2) Limited Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2017021911A1 (en) 2015-08-04 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
KR20180036996A (ko) 2015-08-04 2018-04-10 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 조합 치료 및 그의 용도 및 방법
EP3331917A1 (en) 2015-08-04 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination treatments and uses and methods thereof
WO2017021912A1 (en) 2015-08-06 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combined tlrs modulators with anti ox40 antibodies
EP3331565A1 (en) 2015-08-06 2018-06-13 GlaxoSmithKline Intellectual Property Development Ltd Tlr4 agonists and compositions thereof and their use in the treatment of cancer
TW201716084A (zh) 2015-08-06 2017-05-16 葛蘭素史克智慧財產發展有限公司 組合物及其用途與治療
EP3331919A1 (en) 2015-08-07 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
EP4015537A1 (en) 2015-12-01 2022-06-22 GlaxoSmithKline Intellectual Property Development Limited Combination treatments and uses and methods thereof
TWI704154B (zh) 2015-12-03 2020-09-11 英商葛蘭素史克智慧財產發展有限公司 新穎化合物
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
SG10201912074PA (en) 2016-03-18 2020-02-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
HRP20220936T1 (hr) 2016-04-07 2022-10-28 Glaxosmithkline Intellectual Property Development Limited Heterociklički amidi korisni kao modulatori proteina
JP2019521166A (ja) 2016-07-20 2019-07-25 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｐｅｒｋ阻害剤としてのイソキノリン誘導体
WO2018025221A1 (en) 2016-08-04 2018-02-08 Glaxosmithkline Intellectual Property Development Limited Anti-icos and anti-pd-1 antibody combination therapy
WO2018053354A1 (en) 2016-09-15 2018-03-22 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
CN117510491A (zh) 2016-12-23 2024-02-06 阿尔维纳斯运营股份有限公司 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
MX2019007646A (es) 2016-12-23 2019-09-06 Arvinas Operations Inc Moleculas quimericas dirigidas a la proteolisis del egfr y metodos asociados de uso.
US20190375847A1 (en) 2017-02-15 2019-12-12 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
ES2952265T3 (es) 2017-05-02 2023-10-30 Novartis Ag Terapia combinada que comprende un inhibidor de Raf y trametinib
CN110831582B (zh) 2017-07-05 2023-08-11 诺华股份有限公司 药物组合物
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
UY37866A (es) 2017-09-07 2019-03-29 Glaxosmithkline Ip Dev Ltd Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
CA3077337A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
US20210238172A1 (en) 2017-10-05 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators and methods of using the same
WO2019106605A1 (en) 2017-12-01 2019-06-06 Board Of Regents, The University Of Texas System Combination treatment for cancer
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
CN113194752A (zh) 2018-06-01 2021-07-30 康奈尔大学 Pi3k相关疾病或病症的组合疗法
WO2020030571A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
WO2020030570A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
WO2020029799A1 (en) * 2018-08-07 2020-02-13 Metagone Biotech Inc. Ammonium salts of 3-(3,5-dibromo-4-hydroxybenzyliden)-5-indo-1,3-dihydroindol-2-one and uses thereof
CN117224541A (zh) * 2018-09-18 2023-12-15 北京强新生物科技有限公司 肥胖症的治疗
AR117206A1 (es) 2018-11-30 2021-07-21 Glaxosmithkline Ip Dev Ltd Derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido útiles en la terapia para el vih y para el tratamiento del cáncer
MX2021009189A (es) 2019-02-01 2021-11-12 Glaxosmithkline Ip Dev Ltd Belantamab mafodotin en combinación con pembrolizumab para el tratamiento del cáncer.
ES3025633T3 (en) 2019-05-13 2025-06-09 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
JP2022533194A (ja) 2019-05-16 2022-07-21 スティングセラ インコーポレイテッド ベンゾ［ｂ］［１，８］ナフチリジン酢酸誘導体および使用方法
US20220227761A1 (en) 2019-05-16 2022-07-21 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
KR20220026585A (ko) 2019-06-26 2022-03-04 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Il1rap 결합 단백질
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2021046289A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and ipilimumab
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
CN114981265B (zh) 2019-12-18 2025-01-03 Ctxt私人有限公司 化合物
EP4096718A1 (en) 2020-01-28 2022-12-07 GlaxoSmithKline Intellectual Property Development Limited Combination treatments and uses and methods thereof
JP7834721B2 (ja) 2020-08-28 2026-03-24 アルビナス・オペレーションズ・インコーポレイテッド 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法
CN114573453B (zh) * 2020-12-02 2024-12-03 荆楚理工学院 一种选择性的羧酸酯裂解方法
CN117677398A (zh) 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品
KR102566028B1 (ko) * 2021-08-10 2023-08-10 계명대학교 산학협력단 신규한 다중 단백질 키나아제 억제제
CN114671887A (zh) * 2021-10-29 2022-06-28 四川大学华西医院 一种二氢吲哚酮类化合物的制备及其抗肿瘤应用
AR129423A1 (es) 2022-05-27 2024-08-21 Viiv Healthcare Co Compuestos útiles en la terapia contra el hiv
EP4584258A1 (en) 2022-09-07 2025-07-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
ATE243034T1 (de) * 1996-01-17 2003-07-15 Taiho Pharmaceutical Co Ltd Intimale verdickungsinhibitoren
WO1998007695A1 (en) 1996-08-23 1998-02-26 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005532284A (ja) * 2002-04-03 2005-10-27 アラーガン、インコーポレイテッド キナーゼ阻害物質としての（３ｚ）−３−（３−ヒドロ−イソベンゾフラン−１−イリデン）−１，３−ジヒドロ−２ｈ−インドール−２−オン類
WO2005080392A1 (ja) * 2004-02-19 2005-09-01 Takeda Pharmaceutical Company Limited ピラゾロキノロン誘導体およびその用途
US7842701B2 (en) 2004-02-19 2010-11-30 Takeda Pharmaceutical Company Limited Pyrazoloquinolone derivative and use thereof
JP2007528884A (ja) * 2004-03-12 2007-10-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規なシクロアルキル含有５−アシルインドリノン、その製法及びその医薬品としての使用
JP2010538091A (ja) * 2007-09-06 2010-12-09 ボストン バイオメディカル， インコーポレイテッド キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用
JP2015129152A (ja) * 2007-09-06 2015-07-16 ボストン バイオメディカル， インコーポレイテッド キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用
JP2016180013A (ja) * 2007-09-06 2016-10-13 ボストン バイオメディカル， インコーポレイテッド キナーゼ阻害剤の組成物ならびに癌およびキナーゼに関連する他の疾患の治療のためのそれらの使用
JP2016513656A (ja) * 2013-03-13 2016-05-16 ボストン バイオメディカル， インコーポレイテッド がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての３−（アリールまたはヘテロアリール）メチレンインドリン−２−オン誘導体

Also Published As

Publication number Publication date
EP1003721A1 (en) 2000-05-31
ES2272008T3 (es) 2007-04-16
US6268391B1 (en) 2001-07-31
DE69836332D1 (de) 2006-12-14
DE69836332T2 (de) 2007-12-13
ZA987037B (en) 2000-02-07
GB9716557D0 (en) 1997-10-08
MA26529A1 (fr) 2004-12-20
AR016789A1 (es) 2001-08-01
AU9158498A (en) 1999-03-16
ATE344241T1 (de) 2006-11-15
PE112699A1 (es) 1999-11-16
WO1999010325A1 (en) 1999-03-04
EP1003721B1 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
JP2002514228A (ja) 受容体チロシンキナーゼ阻害剤、特にｒａｆキナーゼ阻害剤としてのベンジリン−１，３−ジヒドロ−インドール−２−オン誘導体
TW520358B (en) Substituted oxindole derivatives
US7576091B2 (en) Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases
ES2199156T3 (es) Derivados de aza-oxindol sustituidos.
WO1999021859A1 (en) Azaoxindole derivatives
JP2002540097A (ja) タンパク質チロシンキナーゼおよびタンパク質セリン／トレオニンキナーゼ阻害剤としての３−（アニリノメチレン）オキシインドール
JPS6256486A (ja) インド−ル誘導体、その製法及びこれを含有する心臓−及び循環疾病の予防もしくは治療のための薬剤
EP1339680A1 (en) Substituted oxindole derivatives as tyrosine kinase inhibitors
BRPI0720525A2 (pt) Inibidores de quinase mapk/erk
JP2006509765A (ja) 新規化合物
WO2002020513A1 (en) Oxindole derivatives
TW200825083A (en) Novel fluorene derivatives, compositions containing them and use thereof
ES2230337T3 (es) Derivados de oxindol.
Yoo et al. Synthesis and biological evaluation of indazole-4, 7-dione derivatives as novel BRD4 inhibitors
CZ2000798A3 (cs) Substituované oxindolové deriváty
MXPA00002254A (en) Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050803

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090407

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20090727

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090901